[go: up one dir, main page]

AR046321A1 - Compuestos de lactamas macrociclicas, procedimientos de preparacion y composiciones farmaceuticas. - Google Patents

Compuestos de lactamas macrociclicas, procedimientos de preparacion y composiciones farmaceuticas.

Info

Publication number
AR046321A1
AR046321A1 ARP040104052A ARP040104052A AR046321A1 AR 046321 A1 AR046321 A1 AR 046321A1 AR P040104052 A ARP040104052 A AR P040104052A AR P040104052 A ARP040104052 A AR P040104052A AR 046321 A1 AR046321 A1 AR 046321A1
Authority
AR
Argentina
Prior art keywords
alkyl
diyl
cycloalkyl
hydrogen
tetrahydro
Prior art date
Application number
ARP040104052A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR046321A1 publication Critical patent/AR046321A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

El presente se refiere a su preparación, y composiciones farmacéuticas que los comprenden. Reivindicación 1: Un compuesto de la fórmula (1), en donde: R1 es CH(Re)C(=O)N(Ra)Rb o (CH2)kN(Rc)Rd, en donde K es 0, 1 ó 2; Ra y Rb, independientemente, son hidrógeno o un grupo alquilo C1-8 opcionalmente sustituido, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-4, arilo, arilalquilo C1-4, heteroarilo o heteroarilalquilo C1-4; Rc y Rd, independientemente, son hidrógeno o un grupo alquilo C1-8 opcionalmente sustituido, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-4, arilo, arilalquilo C1-4, heteroarilo, heteroarilalquilo C1-4, croman-4-ilo, isocroman-4-ilo, tiocroman-4-ilo, isotiocroman-4-ilo, 1,1-dioxo-1l*6*-tiocroman-4-ilo, 2,2-dioxo- 2l*6*-isotiocroman-4-ilo, 1,2,3,4-tetrahidro-quinolin-4-ilo, 1,2,3,4-tetrahidro-isoquinolin-4-ilo, 1,2,3,4-tetrahidro-naftalen-1-ilo, 1,1-dioxo-1,2,3,4-tetrahidro-1l*6*-benzo[e][1,2]tiazin-4-ilo, 2,2-dioxo-1,2,3,4-tetrahidro-2l*6*benzo[c][1,2]tiazin- 4-ilo, 1,1-dioxo-3,4-dihidro-1H-1l*6*[c][1,2]oxatiin-4-ilo, 2,2-dioxo-3,4-dihidro-2H-2l*6*[e][1,2]oxatiin-4-ilo, 2,3,4,5-tetrahidro-benzo[b]oxepin-5-ilo o 1,2,3,4-tetrahidro-benzo[c]oxepin-5-ilo, o Ra y Rb, o Rc y Rd junto con el átomo de nitrógeno al cual están unidos, forman un grupo pirrolidinilo opcionalmente sustituido, 1-piperidinilo, 4-morfolinilo o piperazinilo; y Re es alquilo C1-8 opcionalmente sustituido, alcoxi C1-4-alquilo C1-4, cicloalquilo C3-7 o cicloalquilo C3-7-alquilo C1-4; R2 es hidrógeno o alquilo C1-4; R3 es hidrógeno, alquilo C1-6 o un grupo alquilo C1-6OC(=O)NH, cicloalquilo C3-7OC(=O)NH, cicloalquilo C3-7-alquilo C1-4OC(=O)NH, arilalquilo C1-4OC(=O)NH, heteroarilalquilo C1-4OC(=O)NH, alquilo C1-4OC(=O)NH, cicloalquilo C3-7OC(=O)NH, ariloOC(=O)NH, arilalquilo C1-4OC(=O)NH, heteroariloOC(=O)NH, o heteroarilalquilo C1-4OC(=O)NH; U es un enlace CF2, CF2CF2, CHF, CHFCHF, cicloprop-1,2-ileno, alquilenoxi C1-3, alquileno C1-8, NRg o un anillo aromático o heteroaromático, cuyo anillo está opcionalmente sustituido con halógeno, alcoxi C1-4, hidroxi o alquilo C1-4, en donde Z y V están en la posición orto o meta uno con respecto del otro, en donde Rg es hidrógeno, alquilo C1-8 o cicloalquilo C3-7; V es CH=CH, cicloprop-1,2-ileno, CH2CH(OH), CH(OH)CH2 o CRhRhCRhRh, en donde cada Rh, independientemente, es hidrógeno, flúor o alquilo C1-4; W es alquileno C1-6, O, S, S(=O)2, C(=O), C(=O)O, OC(=O), C(Rf)C(=O), C(=O)NRf o NRf, en donde Rf es hidrógeno o alquilo C1-4; X es un grupo alcanililideno C1-4 opcionalmente sustituido, alquileno C1-4, cicloalquileno C3-7, piperidin-diilo, pirrolidin-diilo, benzotiazol-4,6-diilo, benzoxazol-4,6-diilo, 1H-benzotriazol-4,6-diilo, imidazol[1,2-a]piridin-6,8- diilo, benzo-[1,2,5]oxadiazol-4,6-diilo, benzo[1,2,5]tiadiazol-4,6-diilo, 1H-indazol-1,6-diilo, 1H-bencimidazol-4,6-diilo o 1H-indazol-1,6-diilo o un anillo aromático o heteroaromático opcionalmente sustituido, en donde Y y C(=O)NR2 están en la posición meta uno con respecto del otro; Y es un enlace, O, S(=O)2, S(=O)2NRg, N(Rg)S(=O)2, NRg, C(Rg)OH, C(=O)NRg, N(Rg)C(=O), C(=O)N(Rg)O o ON(Rg)C(=O), en donde Rg es hidrógeno, alquilo C1-8 o cicloalquilo C3-7; Z es O, CH2, CF2, CHF, cicloprop- 1,2-ileno o un enlace; y n es de 0 a 5, el número de átomos de anillo incluidos en el anillo macrocíclico siendo 14, 15, 16 o 17, en forma de base libre o en forma de sal de adición de ácido.
ARP040104052A 2003-11-05 2004-11-04 Compuestos de lactamas macrociclicas, procedimientos de preparacion y composiciones farmaceuticas. AR046321A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0325830.8A GB0325830D0 (en) 2003-11-05 2003-11-05 Organic compounds

Publications (1)

Publication Number Publication Date
AR046321A1 true AR046321A1 (es) 2005-11-30

Family

ID=29725994

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104052A AR046321A1 (es) 2003-11-05 2004-11-04 Compuestos de lactamas macrociclicas, procedimientos de preparacion y composiciones farmaceuticas.

Country Status (15)

Country Link
US (2) US7612055B2 (es)
EP (1) EP1682521A1 (es)
JP (1) JP4628366B2 (es)
KR (1) KR20060110289A (es)
CN (1) CN1902182A (es)
AR (1) AR046321A1 (es)
AU (1) AU2004291276B2 (es)
BR (1) BRPI0416276A (es)
CA (1) CA2544751A1 (es)
GB (1) GB0325830D0 (es)
MX (1) MXPA06005032A (es)
PE (1) PE20051006A1 (es)
RU (1) RU2006119504A (es)
TW (1) TW200530203A (es)
WO (1) WO2005049585A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115747B2 (en) * 2002-06-20 2006-10-03 Pharmacia & Upjohn Company Process for preparing oxazole intermediates
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
GB0500683D0 (en) 2005-01-13 2005-02-23 Novartis Ag Organic compounds
RU2007130794A (ru) * 2005-01-13 2009-02-20 Новартис АГ (CH) Макроциклические соединения для применения в качестве ингибиторов bace
US7338974B2 (en) 2005-08-12 2008-03-04 Bristol-Myers Squibb Company Macrocyclic diaminopropanes as beta-secretase inhibitors
JP5173807B2 (ja) * 2005-08-19 2013-04-03 エミスフェアー・テクノロジーズ・インク 活性剤を送達するためのシクロプロピル化合物および組成物
PT1966198E (pt) 2005-10-25 2011-05-13 Janssen Pharmaceutica Nv Derivados de 2-amino-3,4-di-hidro-pirido[3,4-d]pirimidina ?teis como inibidores de beta-secretase (bace)
GB0526614D0 (en) * 2005-12-30 2006-02-08 Novartis Ag Organic compounds
WO2007092846A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007092854A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007092839A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
KR20090039726A (ko) * 2006-07-20 2009-04-22 노파르티스 아게 Ｂａｃｅ 억제제로서 유용한 마크로시클릭 화합물
RU2009105764A (ru) * 2006-07-20 2010-08-27 Новартис АГ (CH) Макроциклические соединения, применимые в качестве ингибиторов васе
US7678784B2 (en) 2006-11-20 2010-03-16 Bristol-Myers Squibb Company Oxime-containing macrocyclic acyl guanidines as β-secretase inhibitors
US7772221B2 (en) 2007-02-09 2010-08-10 Bristol-Meyers Squibb Company Diaminopropane derived macrocycles as inhibitors of β amyloid production
WO2008116141A1 (en) 2007-03-21 2008-09-25 Emisphere Technologies, Inc. Allylqxy and alkyloxy benzoic acid delivery agents
US7732434B2 (en) 2007-04-20 2010-06-08 Bristol-Myers Squibb Company Macrocyclic acyl guanidines as beta-secretase inhibitors
WO2008135488A1 (en) * 2007-05-04 2008-11-13 Medivir Ab Aspartyl protease inhibitors
CA2713998A1 (en) 2008-01-28 2009-08-06 Janssen Pharmaceutica N.V. 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of.beta.-secretase (bace)
BRPI0907061A2 (pt) 2008-01-29 2015-07-07 Janssen Pharmaceutica Nv Derivados de 2-aminoquinolina úteis como inibidores de beta-secretase (base)
WO2010058577A1 (ja) * 2008-11-20 2010-05-27 株式会社カネカ 不飽和アミノカルボン酸誘導体の製造方法
CN103370331B (zh) 2011-02-08 2017-02-15 默克专利股份有限公司 用于治疗关节病的氨基他汀衍生物
PH12013501934A1 (en) 2011-03-18 2022-04-08 Bayer Ip Gmbh N-(3-carbamoylphenyl)-1h-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests
EP2877485B1 (de) 2012-07-24 2018-03-14 Merck Patent GmbH Hydroxystatin-derivate zur behandlung von arthrose
US9663475B2 (en) 2013-02-25 2017-05-30 Merck Patent Gmbh 2 amino-3,4-dihydrcquinazoline derivatives and the use thereof as cathepsin D inhibitors
CN105451754A (zh) 2013-08-06 2016-03-30 默克专利股份有限公司 在关节病的情况下胃酶抑素的关节内施用
US11834515B2 (en) 2017-10-11 2023-12-05 Cornell University Macrocyclic compounds as proteasome inhibitors
WO2021044478A1 (ja) * 2019-09-02 2021-03-11 昭和電工マテリアルズ株式会社 イオン性化合物、有機エレクトロニクス材料、有機層、有機エレクトロニクス素子、有機エレクトロルミネセンス素子、表示素子、照明装置、及び有機エレクトロニクス素子の製造方法
CN116199702B (zh) * 2021-12-01 2026-01-09 上海交通大学医学院附属仁济医院 一种大环内酰胺类化合物、其制备方法及应用
CN116082181B (zh) * 2022-12-12 2025-03-04 爱斯特（成都）生物制药股份有限公司 一种制备3-氨基-5-乙氧基-苯甲酸的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69211637T2 (de) * 1991-04-17 1997-01-30 Hoffmann La Roche Neue dna-gyrase inhibitoren, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
TW343965B (en) * 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
MXPA03011466A (es) * 2001-06-12 2004-07-01 Elan Pharm Inc Macrociclos utiles en tratamiento de enfermedades de alzheimer.
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds
RU2007130794A (ru) * 2005-01-13 2009-02-20 Новартис АГ (CH) Макроциклические соединения для применения в качестве ингибиторов bace
GB0500683D0 (en) * 2005-01-13 2005-02-23 Novartis Ag Organic compounds
GB0526614D0 (en) * 2005-12-30 2006-02-08 Novartis Ag Organic compounds
RU2009105764A (ru) * 2006-07-20 2010-08-27 Новартис АГ (CH) Макроциклические соединения, применимые в качестве ингибиторов васе
KR20090039726A (ko) * 2006-07-20 2009-04-22 노파르티스 아게 Ｂａｃｅ 억제제로서 유용한 마크로시클릭 화합물

Also Published As

Publication number Publication date
CN1902182A (zh) 2007-01-24
RU2006119504A (ru) 2007-12-27
JP4628366B2 (ja) 2011-02-09
WO2005049585A1 (en) 2005-06-02
GB0325830D0 (en) 2003-12-10
US7612055B2 (en) 2009-11-03
BRPI0416276A (pt) 2007-01-23
EP1682521A1 (en) 2006-07-26
US20070072792A1 (en) 2007-03-29
AU2004291276B2 (en) 2009-03-12
CA2544751A1 (en) 2005-06-02
TW200530203A (en) 2005-09-16
US20100022500A1 (en) 2010-01-28
JP2007510002A (ja) 2007-04-19
AU2004291276A1 (en) 2005-06-02
MXPA06005032A (es) 2006-07-06
KR20060110289A (ko) 2006-10-24
PE20051006A1 (es) 2005-12-28

Similar Documents

Publication Publication Date Title
AR046321A1 (es) Compuestos de lactamas macrociclicas, procedimientos de preparacion y composiciones farmaceuticas.
RU2007110531A (ru) Гетероциклические противовирусные соединения
PE20240493A1 (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cancer
AR037731A1 (es) Uso de ureas de benzotiazoles
AR066013A1 (es) Derivados de oxazolidinona, composiciones farmaceuticas que los contienen y su uso en el tratamiento o prevencion de una infeccion bacteriana.
NI201800080A (es) Derivados de pirazolo[1, 5-a]pirazin-4-ilo como inhibidores de jak
AR050186A1 (es) Derivados de amino-piperidina, su preparacion y su aplicacion en terapeutica.
AR035340A1 (es) Compuestos de succinimida heterociclicos fusionados y analogos de los mismos, las composiciones farmaceuticas que los contienen y metodos para preparar dichos compuestos
AR066458A1 (es) Derivados de piperidina, procesos de obtencion y composiciones farmaceuticas.
AR035759A1 (es) Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
AR042532A1 (es) Compuestos de 5,8-dihidro-6h-pirido[2,3-d]pirimidin-7-ona
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR079334A1 (es) Derivados de oxazin amino
AR044294A1 (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa
AR043190A1 (es) Derivados de quinoleina como inhibidores del factor inhibidor de la migracion de macrofagos y metodos para su identificacion. sintesis y composiciones farmaceuticas.
AR042875A1 (es) Mimeticos de glucocorticoides, composiciones farmaceuticas y sus usos
AR082885A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR069804A1 (es) Agonistas del receptor glucocorticoide c20- c21 sustituido
EP1682547A1 (en) Rsv polymerase inhibitors
AR050433A1 (es) Derivados piperidilo de quinazolina e isoquinolina
AR038914A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion para fabricar un medicamento
AR070207A1 (es) Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica
RU2006108799A (ru) N3-замещенные имидазопиридиновые ингибиторы c-kit
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
RU2008130926A (ru) Макроциклические соединения для применения в качестве ингибиторов васе

Legal Events

Date Code Title Description
FB Suspension of granting procedure